small ubiquitin like modifier 4Genealiases: IDDM5 · SMT3H4 · SUMO-4 · dJ281H8.4
Q-omics provides the consensus-scored SUMO4 profile across patient tissues and cancer cell-line models. SUMO4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUMO4 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SUMO4 RNA expression shows 15,053 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, HNSC, and LAML as cancer lineages where SUMO4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUMO4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUMO4 survival associations across molecular data types. SUMO4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUMO4 RNA expression–survival associations across cancer types. High SUMO4 expression shows unfavorable associations in KIRC, STAD, ACC, THCA and MESO, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUMO4 RNA expression.
This table summarizes SUMO4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SUMO4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUMO4 shows higher tumor expression in HNSC, BLCA, LUSC, BRCA, STAD and KIRC. The HNSC box plot shows higher SUMO4 RNA expression in tumor versus normal tissue (log2 FC = +0.253, t-test p < 0.001).
This table shows molecular features associated with SUMO4 in patient tissues and cancer cell lines. In patient samples, SUMO4 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, SUMO4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
